ArticleFrontiers in pharmacology2026

Safety and efficacy of the MNK/VEGFR inhibitor JDB153 combined with the anti-PD-1 antibody serplulimab in patients with advanced pancreatic cancer refractory to standard treatment: a single-arm, phase Ib/II study protocol.

Xiaorui Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.